Breast Cancer Clinical Trial
Official title:
S1008: Feasibility Study of a Physical Activity and Dietary Change Weight Loss Intervention In Breast and Colorectal Cancer Survivors, Phase II
RATIONALE: Physical activity, diet, and counseling may help breast and colorectal cancer
survivors to lose weight and improve their quality of life.
PURPOSE: This phase II trial studies how well exercise, diet, and counseling work in
improving physical activity and weight loss in overweight women who are breast and colorectal
cancer survivors.
OBJECTIVES:
Primary
- To determine the feasibility of a 12-month community-based combined physical activity
and dietary change weight-loss intervention in overweight and sedentary female breast
and colorectal cancer survivors recruited via the Southwest Oncology Group (SWOG).
- To estimate the effect size of the intervention on weight loss at 12 months.
Secondary
- To measure changes in anthropometric measures from baseline (body mass index [BMI],
waist and hip circumference) at 6 and 12 months and body composition (% body fat as
assessed by dual-energy X-ray absorptiometry [DXA] scan) at 12 months.
- To measure changes in minutes spent per week in moderate-to-vigorous aerobic activity
from baseline using Curves attendance records and a 7-day physical activity assessment
at 6 and 12 months.
- To measure changes from baseline to 6 and 12 months in dietary intake of carotenoids via
serum carotenoid measures.
- To assess changes from baseline to 6 and 12 months in perceived benefit of dietary
change, physical activity, and weight loss after a cancer diagnosis.
- To measure changes from baseline in metabolic and hormonal biomarkers associated with
breast and colorectal cancer recurrence risk (fasting insulin, fasting glucose,
hemoglobin A1C, bioavailable estradiol, free testosterone, and adiponectin) at 6 and 12
months.
- To assess changes from baseline in anxiety, depression, fatigue, sleep, satisfaction
with social roles, pain, and physical function using the PROMISE-43 at 6 and 12 months.
- To assess baseline predictors (medical history, health behaviors, quality of life) of
subjects who adhere to and complete the intervention.
- To assess the diversity of subjects who enroll and complete the intervention.
- To assess the availability and acceptability of the Curves fitness centers at 12 months.
- To explore changes in DNA methylation.
- To assess the intervention and study process via open-ended interviews with SWOG sites
and Curves franchises.
- To measure changes in anthropometric measures and assess feasibility of extended
follow-up at 24 and 36 months.
- To assess the safety of the Curves® fitness centers for this population by assessing
self-reported changes in lymphedema and any injuries as measured at 6 and 12 months.
OUTLINE: Participants are stratified according to type of cancer (breast vs colorectal).
Participants are instructed to practice 30-45 minutes of medium-to-hard exercise 5-7 days a
week at a Curves fitness center (paid by study) or outside Curves for 12 months. Participants
receive written materials on physical activity guidelines for survivors and a pedometer to
track their physical activity outside Curves. They also receive the Curves Fitness & Weight
Management Plan and are instructed to follow a "higher carbohydrate" diet plan, which
promotes a 1,500 kcal/day diet that is high in fruit and vegetables consisting of 30%
protein, 45% carbohydrates, and 25% fat. In addition, participants receive the dietary
guidelines for cancer survivors, which recommend eating 5 or more servings of
fruit/vegetables per day, a diet high in whole grains, low in saturated fat, low in sugary
foods, and low in alcohol. Participants receive 14 behavioral-counseling sessions by
telephone with the goal to increase intervention adherence and participation retention. Each
session lasts 40 minutes and occurs weekly on weeks 1-5 and then every 6 weeks by month 6.
Participants receive monthly email newsletters with health tips and motivational messages to
encourage adherence and retention to the study program. Counselors also conduct three 24-hour
dietary recall assessments and 1 physical activity assessment at 6 and 12 months.
Participants complete a PROMIS-43 quality-of-life questionnaire at 6 and 12 months via
internet, mail, or telephone.
Participants also undergo blood sample collection at baseline and at 6 and 12 months for
fasting glucose and insulin tests, and biomarker studies. Anthropometric measurements
(height, weight, waist, and hip circumference) are also collected.
After completion of study intervention, participants are followed up at 24 and 36 months.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |